Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Today

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jul 15, 2022 12:38pm

148 Views

Post# 34827292

RE:Today

I remind you this analyst wrote this report yesterday and it did not mention either cancer or the financing, the two most important news items in TH's recent history. He also made mention of Egrifta being approved in Mexico. Why, I have no idea, since TH has no marketing effort there, so it is totally irrelevant. He may be a decent analyst but he is mailing it in when it comes to TH. This is as much TH's fault as it is his.